Eton Pharmaceuticals, Inc. ETON Short-term debt and current portion of long-term debt

Short-term debt and current portion of long-term debt at other companies

CotyCOTY

$2.1M-77.7%

Aon plcAON

$1.12B-16.8%

IntelINTC

$2B-61.8%

Quanta ServicesPWR

$689.69M+836%

PhiniaPHIN

$24M-4.0%

NXP SemiconductorsNXPI

$750M-50.0%

Other financials

Income statement

See full

Revenue$24.3M+40.4%

Gross profit$14.7M+49.4%

Operating income$2.4M+614%

Net income$1.6M+199%

EPS (diluted)$0.05+183%

Balance sheet

See full

Cash & equivalents$19.7M+12.9%

Total debt$31.3M+3.7%

Total equity$30.6M+25.2%

Total assets$97.7M+16.3%

Cash flow

See full

Operating cash flow$7.4M+254%

CapEx$75.0K—

Free cash flow$7.3M+251%

Valuation

See full

Market cap$930.79M+162%

Enterprise value$942.39M+156%

P/S10.7×+3.4×

Profitability

See full

Gross margin54.8%-3.7pp

Operating margin-15.1%—

Net margin-9.5%-2.7pp

FCF margin17.1%—

Returns & leverage

See full

Return on equity-34.2%+0.9pp

Debt / equity1×-0.2×

Current ratio1.2×-0.8×

Where this comes from

Reported directly by Eton Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtCurrent.

The official record: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eton Pharmaceuticals, Inc.'s short-term debt and current portion of long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Eton Pharmaceuticals, Inc.'s short-term debt and current portion of long-term debt?: Eton Pharmaceuticals, Inc. (ETON) reported short-term debt and current portion of long-term debt of $11.81M in Q1 2026.